WO2018133110A1 - Dispersion solide de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation - Google Patents
Dispersion solide de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation Download PDFInfo
- Publication number
- WO2018133110A1 WO2018133110A1 PCT/CN2017/072230 CN2017072230W WO2018133110A1 WO 2018133110 A1 WO2018133110 A1 WO 2018133110A1 CN 2017072230 W CN2017072230 W CN 2017072230W WO 2018133110 A1 WO2018133110 A1 WO 2018133110A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- saponin
- solid dispersion
- solution
- povidone
- preparation
- Prior art date
Links
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- MFIXLWYJTVEVGO-YHGWSDCJSA-N O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CC[C@H]([C@@]([C@H]14)(C)O)C)C(O)=O)[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CC[C@H]([C@@]([C@H]14)(C)O)C)C(O)=O)[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O MFIXLWYJTVEVGO-YHGWSDCJSA-N 0.000 title abstract description 5
- MFIXLWYJTVEVGO-DNOHTNDQSA-N ilexoside B Natural products C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O[C@H]6[C@@H]([C@H]([C@@H](CO6)O)O)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O MFIXLWYJTVEVGO-DNOHTNDQSA-N 0.000 title abstract description 5
- WFDGBBHAJUVQKE-UHFFFAOYSA-N ziyu-glycoside II Natural products CC1(O)CCCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OCC(O)C(O)C6O)C(C)(C)C5CCC34C)C12)C(=O)O WFDGBBHAJUVQKE-UHFFFAOYSA-N 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 23
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 210000000601 blood cell Anatomy 0.000 claims abstract description 11
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 10
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 10
- 206010065553 Bone marrow failure Diseases 0.000 claims abstract description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 62
- 229930182490 saponin Natural products 0.000 claims description 62
- 150000007949 saponins Chemical class 0.000 claims description 58
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 34
- 229940069328 povidone Drugs 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 16
- 229920003081 Povidone K 30 Polymers 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 238000001704 evaporation Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 42
- 238000002474 experimental method Methods 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 239000012876 carrier material Substances 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 239000005630 Diquat Substances 0.000 description 4
- -1 Diquat Saponin Chemical class 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 241000510678 Falcaria vulgaris Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 229920006061 Kelon® Polymers 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000008071 Parvoviridae Infections Diseases 0.000 description 1
- 206010057343 Parvovirus infection Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- the invention relates to a solid dispersion of saponin II and a preparation method thereof, and belongs to the field of medicine.
- Myelosuppression is a clinically common hematopoietic disease that can occur in radiation therapy and/or chemotherapy of various systemic neoplastic diseases, radiation damage caused by ionizing radiation, viral hepatitis, parvovirus infection or drugs (chloramphenicol). , benzene, sulfonamides, anti-epileptic drugs, sedatives, anti-thyroid drugs, anti-diabetes drugs, anti-malaria, sleeping pills and other factors. Myelosuppression can cause damage to the bone marrow microenvironment, hematopoietic stem cells, hematopoietic growth factors, etc., and the granulosa, red, and megakaryocyte systems are inhibited.
- Diltiazem II is a mantle from the genus Rosaceae or A pharmacologically active compound is extracted from the roots of the longleaf mantle.
- CN101119740A discloses the use of saponin II in the preparation of a medicament for increasing red blood cells and hemoglobin.
- saponin II is not effective, and it is often difficult to obtain a better blood cell level and a bone marrow suppression treatment when used alone. Therefore, there is an urgent need to improve the efficacy of the saponin II and promote the clinical application of the drug.
- the present invention provides a solid dispersion of saponin II which is prepared from the following raw materials by weight ratio: 1 part of saponin II and 4-30 parts of povidone.
- the povidone is PVP K30.
- the invention provides a preparation method of the solid dispersion, comprising the following steps:
- organic solvent described in step a is anhydrous ethanol.
- the mass to volume ratio of the saponin II to the solvent in the saponin II solution described in step a is 1:100; the mass to volume ratio of povidone to solvent in the povidone solution is (1: 4) ⁇ (5:1).
- step c was carried out by placing the mixture in a 60 ° C water bath and evaporating the solvent.
- the present invention provides the use of the solid dispersion for the preparation of a medicament for increasing the number of blood cells and hemoglobin.
- the present invention provides the use of the solid dispersion for the preparation of a medicament for the treatment and/or prevention of myelosuppression.
- the present invention provides a method of increasing the number of blood cells and hemoglobin using the solid dispersion.
- the present invention provides a method of treating and/or preventing myelosuppression using the solid dispersion.
- the reason that the effect of the saponin II on raising the blood cell level is poor is that the solubility is low and the gastrointestinal absorption rate is small, resulting in low bioavailability of the drug and limiting the exertion of its efficacy.
- the invention uses the povidone as a carrier material to prepare the saponin II as a solid dispersion, which can significantly improve the solubility of the drug, and the dissolution rate of the solid dispersion is as high as 85%.
- the solid dispersion of the saponin II of the present invention can significantly increase the number of WBC, RBC, PLT, NEUT and HGB in the peripheral blood, and the drug effect is obviously superior to that of the saponin II drug, indicating that the present invention
- the invention can improve the bioavailability of the main drug and increase the blood cell number and prevent bone marrow suppression by preparing the saponin II into a solid dispersion.
- the raw materials and equipment used in the specific embodiments of the present invention are known products and are obtained by purchasing commercially available products.
- PEG 8000, PEG 6000, PEG 4000, F68 were purchased from Chengdu Kelon Chemical Reagent Factory; PVP K30 was purchased from Sinopharm Chemical Reagent Co., Ltd.
- Dissolution method Take one tablet of each batch, according to the dissolution method ("Chinese Pharmacopoeia" Appendix XC second method), with pH 6.8PBS 1 000mL as the dissolution medium, the rotation speed is 100r ⁇ min -1 , temperature ( 37 ⁇ 0.5)°C, sample 5mL at 0, 5, 15, 20, 25min, filter with 0.45 ⁇ m microporous membrane, place the filtrate in a 100mL volumetric flask, dilute to the mark with pH 6.8PBS, shake well, UV- Visible spectrophotometry (Chinese Pharmacopoeia Appendix IVA) measured absorbance at 345nm wavelength; after 25min sampling, the whole solution was transferred to a beaker, heated and stirred at 100 ° C for 2 ⁇ 3min, cooled to 37 ° C, according to the above method After sampling and dilution, the absorbance measured by the eluate after treatment at 100 ° C was the denominator, and the absorbance measured at each time point was taken as
- the solubility of the saponin II drug in the early stage of the experiment was determined to be only 0.032 mg/ml. It can be seen from Table 1 that when the solid dispersion of the saponin II is prepared by using the povidone-based carrier material of the present invention, the solubility of the drug can be significantly improved, and the dissolution degree is highest; if other carrier materials, such as poloxamer, are used, With polyethylene glycol and the like, the dissolution rate of the solid dispersion is greatly reduced, and the solubility of the drug is not as obvious as that of PVP K30.
- Test drug saponin II solid dispersion (prepared according to Example 2), saponin II.
- tool drugs cyclophosphamide.
- mice All animals were fed ad libitum for 1 week and were randomly divided into: blank group; model group; saponin II solid dispersion group, which were formulated into 0.5 mg ⁇ kg -1 , 5 mg ⁇ kg -1 , 10 mg ⁇ kg -1 .
- the suspension was prepared before use; the saponin II group was formulated into a 10 mg ⁇ kg -1 suspension and prepared before use.
- the other groups of mice were intraperitoneally injected with cyclophosphamide physiological saline solution at a dose of 50 mg ⁇ kg -1 for 3 consecutive days, and the blank mice were injected with the same volume of normal saline in the tail vein.
- mice in the blank group and the model group were intragastrically administered with the same volume of normal saline for 7 consecutive days.
- Peripheral blood test Peripheral blood leukocytes (WBC), neutrophils (NEUT) red blood cells (RBC), platelets (PLT), and hemoglobin (HGB) were counted in each experimental group by an automatic blood cell counter.
- WBC Peripheral blood leukocytes
- NUT neutrophils
- RBC red blood cells
- PHT platelets
- HGB hemoglobin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Molecular Biology (AREA)
- Steroid Compounds (AREA)
Abstract
Font l'objet de cette invention une dispersion solide de ziyuglucoside II de Sanguisorba officinalis, son procédé de préparation et ses applications. Cette dispersion solide est constituée des excipients suivants exprimés en parties : 1 partie de ziyuglucoside II de Sanguisorba officinalis et 4-30 parties de polyvinylpyrrolidone en vue de la préparation d'un médicament indiqué pour augmenter les globules sanguins et le taux d'hémoglobine et d'un médicament pour le traitement et/ou la prophylaxie de la myélosuppression. La dispersion solide selon l'invention permet d'augmenter la solubilité du ziyuglucoside de Sanguisorba officinalis et d'atteindre une dissolution de 85 %.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/072230 WO2018133110A1 (fr) | 2017-01-23 | 2017-01-23 | Dispersion solide de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/072230 WO2018133110A1 (fr) | 2017-01-23 | 2017-01-23 | Dispersion solide de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018133110A1 true WO2018133110A1 (fr) | 2018-07-26 |
Family
ID=62907631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2017/072230 WO2018133110A1 (fr) | 2017-01-23 | 2017-01-23 | Dispersion solide de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2018133110A1 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106539763A (zh) * | 2015-09-18 | 2017-03-29 | 四川英路维特医药科技有限公司 | 一种地榆皂苷ⅱ固体分散体及其制备方法 |
-
2017
- 2017-01-23 WO PCT/CN2017/072230 patent/WO2018133110A1/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106539763A (zh) * | 2015-09-18 | 2017-03-29 | 四川英路维特医药科技有限公司 | 一种地榆皂苷ⅱ固体分散体及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| DAI, LIANGMIN ET AL.: "Protective Effect of Tannins from Sanguisorba Officinalis on Cyclophosphamide-induced Myelosuppression in Mice", NATURAL PRODUCT RESEARCH AND DEVELOPMENT, vol. 6, 7 April 2016 (2016-04-07), pages 852 - 859, ISSN: 1001-6880 * |
| YU , QI'NAN: "The Pharmaceutical Research of Sanguisorba Officinalis Dispersing Tablet", CHINA MASTER'S THESES FULL-TEXT DATABASE, vol. 5, 15 May 2016 (2016-05-15), pages E057 - 360, ISSN: 1674-0246 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11040020B2 (en) | Sulfonamide pharmaceutical composition | |
| CN106137973A (zh) | 一种复方磺胺氯吡嗪钠可溶性粉及其制备方法 | |
| CN112370436A (zh) | 一种预防或治疗脑缺血再灌注损伤纳米药物及其制备方法与应用 | |
| CN111214446B (zh) | 一种供注射用法匹拉韦l-精氨酸盐冻干制剂 | |
| CN111012819A (zh) | 一种猴耳环提取物纳米制剂及其制备方法 | |
| CN114796133A (zh) | 一种注射用药物制剂及其制备方法 | |
| EA018636B1 (ru) | Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества | |
| WO2018133110A1 (fr) | Dispersion solide de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation | |
| WO2018133106A1 (fr) | Dispersion solide de ziyuglucoside ii de sanguisorba officinalis, son procédé de préparation et ses applications | |
| CN116019771A (zh) | 一种氟苯尼考可混饮无定形固体分散体制剂及其制备方法和用途 | |
| CN114209656A (zh) | 一种氟苯尼考可溶性粉及其制备方法 | |
| CN106539763A (zh) | 一种地榆皂苷ⅱ固体分散体及其制备方法 | |
| CN106581692A (zh) | 一种地榆皂苷i包合物及其制备方法 | |
| WO2018133105A1 (fr) | COMPLEXE D'INCLUSION D'HYDROXYPROPYL-β-CYCLODEXTRINE DE ZIYUGLUCOSIDE II DE SANGUISORBA OFFICINALIS, SON PROCÉDÉ DE PRÉPARATION ET SES APPLICATIONS | |
| WO2017181653A1 (fr) | Micelle polymère à base de sapogénine de radix sanguisorbae, son procédé de préparation, et son utilisation pharmaceutique | |
| CN112438971A (zh) | 蛋氨酸在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用 | |
| WO2018133109A1 (fr) | Liposome de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation | |
| WO2018133108A1 (fr) | Émulsion de ziyuglucoside ii de sanguisorba officinalis et son procédé de préparation | |
| KR20060039286A (ko) | 경구투여용 항말라리아 배합 제제 및 그의 제조방법 | |
| WO2018133104A1 (fr) | COMPLEXE D'INCLUSION D'HYDROXYPROPYL-β-CYCLODEXTRINE DE ZIYUGLUCOSIDE II DE SANGUISORBA OFFICINALIS, SON PROCÉDÉ DE PRÉPARATION ET SES APPLICATIONS | |
| WO2017177668A1 (fr) | Micelles de polymère de ziyuglycoside ii et procédé de préparation associé | |
| WO2018133112A1 (fr) | Injection d'aglycone de sanguisorba officinalis, son procédé de préparation et ses applications | |
| CN112516125B (zh) | 酪氨酸在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用 | |
| CN119606954B (zh) | 一种替韦立马组合物及其制备方法和应用 | |
| CN104042603B (zh) | γ-氨基丁酸在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17893043 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17893043 Country of ref document: EP Kind code of ref document: A1 |